10/ 725,267

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS	4	OCT 03	MATHDI removed from STN
NEWS	5	OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS	6	OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS	7	OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS	8	OCT 27	Free KWIC format extended in full-text databases
NEWS	9	OCT 27	DIOGENES content streamlined
NEWS	10	OCT 27	EPFULL enhanced with additional content
NEWS	11	NOV 14	CA/CAplus - Expanded coverage of German academic research
NEWS	12	NOV 30	REGISTRY/ZREGISTRY on STN(R) enhanced with experimental spectral property data

NEWS EXPRESS	NOVEMBER 18 CURRENT VERSION FOR WINDOWS IS V8.01, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005. V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT http://download.cas.org/express/v8.0-Discover/
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:03:21 ON 01 DEC 2005

=> file reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

10/ 725,267

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 11:03:30 ON 01 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 29 NOV 2005 HIGHEST RN 868943-57-1
DICTIONARY FILE UPDATES: 29 NOV 2005 HIGHEST RN 868943-57-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
****

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10725267a.str





chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9 12
chain bonds :
7-11 8-10 11-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

10/ 725,267

exact/norm bonds :
3-9 8-9 8-10
exact bonds :
2-7 7-8 7-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10725267b.str





chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9 12
chain bonds :
7-11 8-10 11-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :

10/ 725,267

3-9 8-9 8-10
exact bonds :
2-7 7-8 7-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom

L2 STRUCTURE UPLOADED

=> d 12
L2 HAS NO ANSWERS
L2 STR



Structure attributes must be viewed using STN Express query preparation.

=>
Uploading C:\Program Files\Stnexp\Queries\10725267c.str





chain nodes :
10 11
ring nodes :
1 2 3 4 5 6 7 8 9 12
chain bonds :
7-11 8-10 11-12
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
3-9 8-9 8-10

10/ 725,267

exact bonds :
2-7 7-8 7-11 11-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:Atom

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.

=> s (l1 or l2 or l3) sample
SAMPLE SEARCH INITIATED 11:04:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM (L1 OR L2 OR L3)

=> s (l1 or l2 or l3) full
FULL SEARCH INITIATED 11:04:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L5 0 SEA SSS FUL (L1 OR L2 OR L3)

=> s pyridaz? and pyrrolidin?

10/ 725,267

```
        137119 PYRIDAZ?
        528407 PYRROLIDIN?
L6        1620 PYRIDAZ? AND PYRROLIDIN?

=> d scan 16
```

10/ 725,267

L6 1620 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN
IN 4-Piperidinol, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(3-pyridazinyl)-3-pyrrolidinyl]carbonyl]-3,5-dimethyl-4-phenyl-, (3a,4a,5a)- (9CI)
MF C28 H30 F2 N4 O2
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

10/ 725,267

```
=> s pyridaz? with pyrrolidin?
        137119 PYRIDAZ?
       1572826 WITH
        528407 PYRROLIDIN?
L7           0 PYRIDAZ? WITH PYRROLIDIN?
                 (PYRIDAZ?(W)WITH(W)PYRROLIDIN?)

=> s pyridaz? same pyrrolidin?
        137119 PYRIDAZ?
             7 SAME
        528407 PYRROLIDIN?
L8           0 PYRIDAZ? SAME PYRROLIDIN?
                 (PYRIDAZ?(W)SAME(W)PYRROLIDIN?)

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     369.05     369.26

FILE 'CAPLUS' ENTERED AT 11:06:45 ON 01 DEC 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 1 Dec 2005  VOL 143 ISS 23
FILE LAST UPDATED: 30 Nov 2005  (20051130/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> d his

     (FILE 'HOME' ENTERED AT 11:03:21 ON 01 DEC 2005)

     FILE 'REGISTRY' ENTERED AT 11:03:30 ON 01 DEC 2005
L1             STRUCTURE UPLOADED
L2             STRUCTURE UPLOADED
L3             STRUCTURE UPLOADED
L4           0 S (L1 OR L2 OR L3) SAMPLE
L5           0 S (L1 OR L2 OR L3) FULL
L6        1620 S PYRIDAZ? AND PYRROLIDIN?
L7           0 S PYRIDAZ? WITH PYRROLIDIN?
L8           0 S PYRIDAZ? SAME PYRROLIDIN?
```

10/ 725,267

FILE 'CAPLUS' ENTERED AT 11:06:45 ON 01 DEC 2005

```
=> s l6
L9          523 L6

=> s l9 and (pyrrolidinone or "oxo-pyrrolidinyl")
          11810 PYRROLIDINONE
         147277 "OXO"
           9989 "PYRROLIDINYL"
             22 "OXO-PYRROLIDINYL"
                  ("OXO"(W)"PYRROLIDINYL")
L10           14 L9 AND (PYRROLIDINONE OR "OXO-PYRROLIDINYL")

=> d l10 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 14 ANSWERS - CONTINUE? Y/(N):y
```

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:696342 CAPLUS
DOCUMENT NUMBER: 141:225302
TITLE: Preparation of N-arylheterocycles as melanin concentrating hormone (MCH) antagonists.
INVENTOR(S): Schwink, Lothar; Stengelin, Siegfried; Gossel, Matthias; Boehme, Thomas; Hessler, Gerhard; Stahl, Petra; Gretzke, Dirk
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany
SOURCE: PCT Int. Appl., 390 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004072025	A2	20040826	WO 2004-EP1342	20040213
WO 2004072025	A3	20041223		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10306250	A1	20040909	DE 2003-10306250	20030214
CA 2516118	AA	20040826	CA 2004-2516118	20040213
EP 1597228	A2	20051123	EP 2004-710808	20040213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004220191	A1	20041104	US 2004-779853	20040217

PRIORITY APPLN. INFO.:
DE 2003-10306250 A 20030214
US 2003-488545P P 20030718
WO 2004-EP1342 W 20040213

OTHER SOURCE(S): MARPAT 141:225302
GI



I

AB Title compds. [I; R1, R2 = H, alkyl, alkoxyalkyl, aryloxyalkyl, alkylcarbonyl, alkenylcarbonyl, etc.; R1R2N = atoms to form a 4-10 membered mono-, bi-, or spirocyclic (substituted) ring; R3 = H, alkyl; R4, R5 = H, alkyl, OH, alkoxy, alkylcarbonyloxy, alkylthio; R6-R9 = H, alkyl;

L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
R6R7, R8R9 = O; A, B, D, G = N, CR42; AB, DG = CR42; R42 = H, F, Cl, Br, iodo, CF3, NO2, cyano, OCF3, alkoxy, alkylthio, alkenyl, cycloalkyl, cycloalkoxy, cycloalkenyl, alkynyl, CO2H, etc.; R10 = H, alkyl, alkenyl, alkynyl; X = NR52, O, bond, C:C, C.tplbond.C, etc.; R52 = H, alkyl; E = (substituted) C3-14 carbocyclyl, heterocyclyl; K = bond, O, CH2O, S, SO, CO, C:C, C.tplbond.C, etc.; R11 = H, alkyl, alkoxyalkyl, alkenyl, alkynyl, 3-10 membered (substituted) mono-, bi-, tri- or spirocyclic ring; ER11 = (unsatd.) tricyclic ring; m, n = 0-2], were prepd. Thus, N-[1-(4-aminophenyl)pyrrolidin-3-yl]piperidine was treated with carbonyldiimidazole and then with 4-(4-chlorophenyl)piperidine to give 4-(4-chlorophenyl)piperidine-1-carboxylic acid [4-[3-(acetylmethylamino)pyrrolidin-1-yl]phenyl]amide. The latter at 30 mg/kg orally in female NMRI mice reduced milk consumption by 64%.
IT 748177-20-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-arylheterocycles as MCH antagonists)
RN 748177-20-0 CAPLUS
CN Benzamide, N-[4-[3-(dimethylamino)-1-pyrrolidinyl]phenyl]-4-[(6-methyl-3-pyridazinyl)oxy]- (9CI) (CA INDEX NAME)

PAGE 1-A



L10 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 2-A

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:550948 CAPLUS
DOCUMENT NUMBER: 141:106496
TITLE: Preparation of substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
INVENTOR(S): Janssens, Frans Eduard; Sommen, Francois Maria; De Boeck, Benoit Christian Albert Ghislain; Leenaerts, Joseph Elisabeth
PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056799	A2	20040708	WO 2003-EP51041	20031217
WO 2004056799	A3	20040812		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2508657	AA	20040708	CA 2003-2508657	20031217
EP 1581518	A2	20051005	EP 2003-810849	20031217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:
WO 2002-EP14831 A 20021223
WO 2003-EP51041 W 20031217

OTHER SOURCE(S): MARPAT 141:106496
GI

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Title compds. I [Q = O or NR3; X = covalent bond, -O-, -S-, or -NR3; R1 independently = Ar1, Ar1-alkyl, and di(Ar1)-alkyl; R2 = Ar2, Ar2-alkyl, di(Ar2)-alkyl Het1, Het1-alkyl; R3 independently = H or alkyl; Y = covalent bond, -CO-, -SO2-, >C:CHR or >C:NR, wherein R = H, CN or NO2; M independently = covalent bond, (un)substituted-alkyl, -(un)saturated carbocycle; L = H, alkyloxy, Ar3oxy, alkylamine, etc.; Ar1 = (un)substituted phenyl; Ar2 = (un)substituted naphthalenyl or Ph with substituent(s) selected from halo, alkyl, CN, aminocarbonyl, and alkyloxy; Ar3 = (un)substituted naphthalenyl or Ph with substituent(s) selected from halo, alkyl, CN, amino, alkyloxy, OH, pyridinyl, etc.; Het1 = monocyclic heterocyclic radical selected from pyrrolyl, pyrazolyl, imidazolyl, furanyl, etc.; m = 1 or 2 provided that if m = 2, then n = 1; n = 0-2; p = 1-2; q = 0-1] and their pharmaceutically acceptable salts having neurokinin antagonistic activity, in particular NK1 antagonistic activity, a combined NK1/NK3 antagonistic activity and a combined NK1/NK2/NK3 antagonistic activity, their preparation, compns. comprising them and their use as a medicine, in particular for the treatment of schizophrenia, anxiety, depression, emesis and IBS are disclosed. Thus, e.g., II was prepared by reaction of (2R-trans) 1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-(1-piperazinyl)piperidine (preparation given) and 1-(phenylmethyl)-3-**pyrrolidinone**. The receptor binding values (pIC50) for the h-NK1 ranges for all compds. according to the invention between 10 and 6. In view of their capability to antagonize the actions of tachykinins by blocking the neurokinin receptors, and in particular antagonizing the actions of substance P and Neurokinin B by blocking the NK1, NX2 and NK3 receptors, the compds. according to the invention are useful as a medicine, in particular in the prophylactic and therapeutic treatment of tachykinin-mediated conditions, such as, for instance CNS disorders, in particular schizoaffective disorders, depression, anxiety disorders, stress-related disorders, sleep disorders, cognitive disorders, personality disorders, eating disorders, neurodegenerative diseases, addiction disorders, mood disorders, sexual dysfunction, pain and other CNS-related conditions ; inflammation ; allergic disorders ; emesis ;

L10 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
gastrointestinal disorders, in particular irritable bowel syndrome (IBS); skin disorders ; vasospastic diseases ; fibrosing and collagen diseases ; disorders related to immune enhancement or suppression and rheumatic diseases and body wt. control.

IT **717924-08-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(stereoselective preparation of piperidinylpyrrolidinylpiperazines with tachykinin antagonist activity)

RN 717924-08-8 CAPLUS

CN Piperidine, 1-[3,5-bis(trifluoromethyl)benzoyl]-4-[4-[1-(6-methyl-3-pyridazinyl)-3-pyrrolidinyl]-1-piperazinyl]-2-(phenylmethyl)-, (2R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:354948 CAPLUS
DOCUMENT NUMBER: 140:357361
TITLE: Preparation of pyrazolopyridazines as GSK-3 kinase inhibitors for treating Type II Diabetes
INVENTOR(S): Dickerson, Scott Howard; Tavares, Francis Xavier; Zhou, Huiqiang
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004035588	A1	20040429	WO 2003-US32473	20031014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1551842	A1	20050713	EP 2003-808999	20031014
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-418522P P 20021015
WO 2003-US32473 W 20031014

OTHER SOURCE(S): MARPAT 140:357361
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [wherein D = N, CH; R1 = (un)substituted hetero/aryl; n = 1 or 2; R2 = H, alk(en/yn)yl, haloalkyl, cycloalkyl, halo, heterocyclyl, hetero/aryl, CN, azido, NO2, OH and derivs., CO2H and derivs., CONH2 and derivs., NH2 and derivs. S(O)qH and derivs., etc.; q = 0-2; R3 = Qp-Q1; Q = O, NH and derivs., S(O)q; p = 0 or 1; Q1 = ar/cyclo/halo/alkyl, heteroaryl, (un)substituted aryl, etc.; their salts, solvates, and physiol. functional derivs.] were prepared as GSK3 kinase inhibitors for treating Type II Diabetes mellitus. For example, II was prepared by cycloaddn. of 1-aminopyridazinium iodide (preparation given) with 3-butyn-2-one in CH_2Cl_2, reaction of the methylketone with DMF di-tert-butylacetal in DMF, and cyclocondensation of the α, β-unsatd. ketone with N-cyclopropylguanidine·0.5H_2SO_4 (preparation given) in DMF in the presence of K_2CO_3. I dispayed pIC50 values > 5.0 for the inhibition of GSK3 kinase.

IT **551919-87-0P**, 1-[3-[(4-Pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]propyl]-2-**pyrrolidinone** **551920-35-5P**, N-Cyclopropyl-4-(6-(1-pyrrolidinyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(GSK3 inhibitor; prepn. of pyrazolopyridazines as GSK-3 inhibitors for treating Type II Diabetes)

RN 551919-87-0 CAPLUS

CN 2-Pyrrolidinone, 1-[3-[(4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 551920-35-5 CAPLUS

CN 2-Pyrimidinamine, N-cyclopropyl-4-(6-(1-pyrrolidinyl)pyrazolo[1,5-b]pyridazin-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:143112 CAPLUS
DOCUMENT NUMBER: 140:181457
TITLE: Preparation of phenylpyridazine derivatives as ligands for GABA receptors
INVENTOR(S): Blackaby, Wesley Peter; Blurton, Peter; Burkamp, Frank; Fletcher, Stephen Robert; Jennings, Andrew; Lewis, Richard Thomas; Macleod, Angus Murray; Street, Leslie Joseph; Thomas, Steve; Van Niel, Monique Bodil; Wilson, Kevin
PATENT ASSIGNEE(S): Merck Sharp & Dohme Limited, UK
SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014865	A1	20040219	WO 2003-GB3376	20030804
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2495285	AA	20040219	CA 2003-2495285	20030804
EP 1532120	A1	20050525	EP 2003-784243	20030804
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: GB 2002-18874 A 20020813
GB 2002-29591 A 20021219
WO 2003-GB3376 W 20030804
OTHER SOURCE(S): CASREACT 140:181457; MARPAT 140:181457
GI



I

L10 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
AB 4-Phenylpyridazines I [X1 = H, halogen, alkyl, CF3, alkoxy; X2 = H, halogen; Z = H, halogen, CN, CH2CN, CF3, NO2, OH, alkoxy, CHO, alkoxycarbonyl, (un)substituted aryl, heteroaryl, heteroarylalkoxy; R1 = H, hydrocarbon, heterocyclic, halogen, CN, CF3, NO2, O3SCF3, (un)substituted OH, SH, S(O)H, SO2H, SO2NH2, NH2, CO2H, CONH2, CH:NOH, acyl, aryl, heteroaryl; R2 = H, alkoxycarbonyl] were prepared for use as selective ligands for GABAA receptors, with particularly high affinity for the α2 and/or α3 and/or α5 subunit in the treatment of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders (no data). Thus, Et 2,3-diphenylcycloprop-2-enecarboxylate was treated with CH2N2 to give Et 3,5-diphenylpyridazine-4-carboxylate.
IT **660424-98-6P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylpyridazine derivs. as ligands for GABA receptors)
RN 660424-98-6 CAPLUS
CN [1,1'-Biphenyl]-2-carbonitrile, 2'-fluoro-5'-[6-(2-oxo-1-pyrrolidinyl)-4-pyridazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2003:491232 CAPLUS
DOCUMENT NUMBER: 139:69273
TITLE: Preparation of (pyrazolo[1,5-b]pyridazinyl)pyrimidinamines and analogs as cyclin dependent kinase inhibitors for treatment of cancer
INVENTOR(S): Harris, Phillip Anthony; Jung, David Kendall; Peel, Michael Robert; Reno, Michael John; Rheault, Tara Renae; Stanford, Jennifer Badiang; Stevens, Kirk Lawrence; Veal, James Marvin; Badiang, Jennifer G.; et al.
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 134 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051886	A1	20030626	WO 2002-US39672	20021211
WO 2003051886	C1	20040819		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1463730	A1	20041006	EP 2002-805104	20021211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 2005090507	A1	20050428	US 2003-499179	20021211
JP 2005524609	T2	20050818	JP 2003-552768	20021211

PRIORITY APPLN. INFO.: US 2001-341798P P 20011217
WO 2002-US39672 W 20021211
OTHER SOURCE(S): MARPAT 139:69273
GI



I



II

AB Fused pyridazine derivs. I [wherein D = N or CH; R1 = H, alkyl, alkenyl, alkynyl, alkoxy, halo, CF3, OH, CN, SO0-2-alkyl, or NR4R5; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, haloalkyl, halo, heterocyclyl,

L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(hetero)aryl, CN, N3, NO2, OR8, OR6R8, R6R7, R6R11, OSO2R9, SO0-2R10, COR7, CO2R7, CONR4R5, NHR12C(NR4)NR4R5, OCONR4R5, OCO2R7, C(NR4)NR4R5, NR4R5, OCOR7, or NR8COR8; R3 = QpQ1; R4 and R5 = independently H, (cyclo)alkyl, or COR9; or NR4R5 = heterocyclyl; R6 = (cyclo)alkylene, (cyclo)alkenylene, alkynylene, or (hetero)arylene; R7 = H, (cyclo)alkyl, alkenyl, alkynyl, NR4R5, (hetero)aryl, aralkyl, heterocyclyl, SO0-2R10, COR8, CO2R8, CONR4R5, NHR12C(NR4)NR4R5, OCONR4R5, OCO2R8, C(NR4)NR4R5, NR4R5, OCOR7, or NR8COR8; R8 = H, (cyclo)alkyl, alkenyl, alkynyl, NR4R5, (hetero)aryl, aralkyl, heterocyclyl, or SO2R9; R9 = (halo)alkyl; R10 = H, (cyclo)alkyl, alkenyl, alkynyl, NR4R5, (hetero)aryl, aralkyl, heterocyclyl, COR8, CO2R8, CONR4R5, NHR12C(NR4)NR4R5, OCONR4R5, OCO2R8, C(NR4)NR4R5, NR4R5, or NR8COR8; R11 = OR7, OCONR4R5, OCO2R7, or OCOR7; R12 = alkylene; Q = O, NR8, or SO0-2; Q1 = (cyclo)alkyl, haloalkyl, (un)substituted aryl, heteroaryl, aralkyl, or R6NR4R5; n = 1-2; p = 0-1; and salts solvates, and physiol. functional derivs. thereof] were prepd. as cyclin dependent kinase (CDK) inhibitors. For example, reaction of 1-aminopyridazinium iodide with 3-butyne-2-one in the presence of KOH in H2O provided 1-(pyrazolo[1,5-b]pyridazin-3-yl)ethanone (69%). Coupling of the ethanone with DMF di-tert-Bu acetal afforded (2E)-3-(dimethylamino)-1-pyrazolo[1,5-b]pyridazin-3-yl-2-propen-1-one (70%), which was cyclized with N-cyclopropylguanidine•0.5H2SO4 in DMF to give II (75%). The latter inhibited CDK4 and CDK2 with IC50 values of <0.1 μM and <1.0 μM, resp. Thus, I are useful for the treatment of hyperproliferative diseases, such as cancer (no data).
IT **551919-87-0P**, 1-[3-[[4-(Pyrazolo[1,5-b]pyridazin-3-yl)-2-pyrimidinyl]amino]propyl]-2-**pyrrolidinone 551920-35-5P**, N-Cyclopropyl-4-[6-(1-pyrrolidinyl)pyrazolo[1,5-b]pyridazin-3-yl]-2-pyrimidinamine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(CDK inhibitor; preparation of (pyrazolo[1,5-b]pyridazinyl)pyrimidinamines and analogs as CDC inhibitors for treatment of cancer)
RN 551919-87-0 CAPLUS
CN 2-Pyrrolidinone, 1-[3-[(4-pyrazolo[1,5-b]pyridazin-3-yl-2-pyrimidinyl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 551920-35-5 CAPLUS
CN 2-Pyrimidinamine, N-cyclopropyl-4-[6-(1-pyrrolidinyl)pyrazolo[1,5-b]pyridazin-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:171898 CAPLUS
DOCUMENT NUMBER: 136:232298
TITLE: Pyrazolopyridine compounds and pharmaceutical use thereof as adenosine receptor antagonists
INVENTOR(S): Akahane, Atsushi; Tanaka, Akira; Minagawa, Masatoshi; Itani, Hiromichi; Ohtake, Hiroaki
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018382	A1	20020307	WO 2001-JP7322	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001080188	A5	20020313	AU 2001-80188	20010827
EP 1313733	A1	20030528	EP 2001-958521	20010827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004507542	T2	20040311	JP 2002-523897	20010827
US 2004110763	A1	20040610	US 2003-344894	20030226

PRIORITY APPLN. INFO.: AU 2000-9698 A 20000828
WO 2001-JP7322 W 20010827
OTHER SOURCE(S): MARPAT 136:232298
GI

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Pyrazolopyridines I are disclosed [wherein: R1 = H, (un)substituted lower alkyl or cycloalkyl which may be interrupted by an O or N; R2 = H, halo, or lower alkoxy; R3 = independent substituent(s); and n = 1 to 4; or a salt thereof]. The compds. are adenosine antagonists, and are thus useful for the prevention and/or treatment of a wide variety of medical conditions, e.g., depression, dementia (e.g., Alzheimer's disease, cerebrovascular dementia, dementia accompanying Parkinson's disease, etc.) Parkinson's disease, anxiety, pain, cerebrovascular disease (e.g. stroke, etc.), heart failure, and the like. In particular, treatment of Parkinson's disease and/or associated symptoms is specifically claimed.

Over 330 example compds. are described. For instance, cyclization of 1-amino-4-methoxypyridinium iodide with 3-(benzenesulfonyl)-6-(phenylethynyl)pyridazine, gave 3-(3-phenylsulfonylpyridazin-6-yl)-5-methoxy-2-phenylpyrazolo[1,5-a]pyridine. This compound was hydrolyzed at the phenylsulfinyl group, and the resultant pyridazinone was N-alkylated with NaH/DMF and iso-PrI to give title compound II. In radioligand binding assays, II had Ki values of 0.15 nM for human A1 receptors and 1.38 nM for human A2A receptors. In an anticatalepsy test in mice, 6 tested example compds. I at 3.2 mg/kg orally completely suppressed the cataleptic effects of haloperidol at 0.32 mg/kg i.p.

IT **403490-32-4P**, 5-[2-(1-Pyrrolidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine **403490-57-3P**, 5-[2-(2-Oxo-1-pyrrolidinyl)ethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine **403491-49-6P**, 5-(1-Pyrrolidinylcarbonyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine **403491-82-7P**, N-[2-(1-Pyrrolidinyl)ethyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine-5-carboxamide **403491-94-1P**, 5-(1-Pyrrolidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-pyrazolo[1,5-a]pyridine **403493-08-3P**, 5-(2-Oxo-1-pyrrolidinyl)-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine **403493-46-9P**, 6-[2-(1-Pyrrolidinyl)-2-oxoethoxy]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine **403494-39-3P**, (S)-5-[[2-(Hydroxymethyl)pyrrolidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine **403494-57-5P**, (S)-5-[[2-(Methoxymethyl)pyrrolidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine **403494-63-3P**, (R)-5-[[2-(Methoxymethyl)pyrrolidin-1-yl]carbonyl]-3-(3-oxo-2-isopropyl-2,3-dihydropyridazin-6-yl)-2-phenylpyrazolo[1,5-a]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; prepn. of pyrazolopyridines as adenosine receptor antagonists)

RN 403490-32-4 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[2-phenyl-5-[2-(1-pyrrolidinyl)ethoxy]pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 403490-57-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-[2-(2-oxo-1-pyrrolidinyl)ethoxy]-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 403491-49-6 CAPLUS
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]- (9CI) (CA INDEX NAME)

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 403491-82-7 CAPLUS
CN Pyrazolo[1,5-a]pyridine-5-carboxamide, 3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 403491-94-1 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(1-pyrrolidinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 403493-08-3 CAPLUS
CN 3(2H)-Pyridazinone, 2-(1-methylethyl)-6-[5-(2-oxo-1-pyrrolidinyl)-2-phenylpyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Absolute stereochemistry.



RN 403494-63-3 CAPLUS
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 403493-46-9 CAPLUS
CN Pyrrolidine, 1-[[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-6-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)



RN 403494-39-3 CAPLUS
CN 2-Pyrrolidinemethanol, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 403494-57-5 CAPLUS
CN Pyrrolidine, 1-[[3-[1,6-dihydro-1-(1-methylethyl)-6-oxo-3-pyridazinyl]-2-phenylpyrazolo[1,5-a]pyridin-5-yl]carbonyl]-2-(methoxymethyl)-, (2S)- (9CI) (CA INDEX NAME)

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:573666 CAPLUS
DOCUMENT NUMBER: 133:164010
TITLE: Preparation of caprolactams, piperidinones, and pyrrolidinones as Factor Xa inhibitors in prevention or treatment of thromboses, coronary artery disease, or cerebrovascular disease in mammals
INVENTOR(S): Stein, Philip D.; Bisacchi, Gregory S.; Shi, Yan; O'Connor, Stephen P.; Li, Chi
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 284 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000047207	A1	20000817	WO 2000-US2883	20000202
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2360305	AA	20000817	CA 2000-2360305	20000202
US 6297233	B1	20011002	US 2000-496571	20000202
EP 1156803	A1	20011128	EP 2000-914505	20000202
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 760174	B2	20030508	AU 2000-35887	20000202

PRIORITY APPLN. INFO.: US 1999-119372P P 19990209
US 1999-167428P P 19991124
WO 2000-US2883 W 20000202

OTHER SOURCE(S): MARPAT 133:164010
GI

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



I



II

AB Title chiral compds. [I; R = CN, CONH2, COOCH2CH3, COC6H5, SO2NH2, OCH3, SO2N(CH3)2, SO2CH3, arylsulfonyl, heterocyclosulfonyl, (un)substituted Ph, heterocyclyl, heterocycleocarbonyl, alkoxylcarbonyl, arylaminocarbonyl; R1 = H, arylalkyl; R2 = alkyl, (un)substituted Ph, benzoheterocyclyl, cyclopentyl; R3 = heterocyclylamino, heterocyclyl, alkoxy, cycloalkylamino, OH; n = 0, 1, 2] , pharmaceutically acceptable salts, and stereoisomers are pred. as Factor Xa inhibitors and are useful as anticoagulants (no data). A method for treating cardiovascular diseases associated with thromboses is also provided. Thus, the title compound II was prepared

IT **288075-69-4P 288079-55-0P 288080-02-4P 288080-03-5P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of caprolactams as Factor Xa inhibitors in prevention or treatment of thromboses, coronary artery disease, or cerebrovascular disease in mammals)

RN 288075-69-4 CAPLUS

CN Pyrrolidine, 1-[[(3S)-3-[[(cyanoamino){(2-methylimidazo[1,2-b]pyridazin-6-yl)amino]methylene]amino]hexahydro-2-oxo-1H-azepin-1-yl]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 288079-55-0 CAPLUS

CN Benzamide, N-[[[(3S)-hexahydro-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-azepin-3-yl]amino][(2-methylimidazo[1,2-b]pyridazin-6-yl)amino]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 288080-02-4 CAPLUS

CN 4-Pyridazinecarboxamide, 3,6-dichloro-N-[[[(3S)-hexahydro-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-azepin-3-yl]amino][(2-methyl-5-benzofuranyl)amino]methylene]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 288080-03-5 CAPLUS

CN 3-Pyridazinecarboxamide, N-[[[(3S)-hexahydro-2-oxo-1-[2-oxo-2-(1-pyrrolidinyl)ethyl]-1H-azepin-3-yl]amino][(2-methyl-5-benzofuranyl)amino]methylene]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:534991 CAPLUS
DOCUMENT NUMBER: 133:135229
TITLE: Preparation of cyclic amino-substituted N-aryl or N-heteroaryl cyclic amines as antidepressants
INVENTOR(S): Poss, Michael A.; Tortolani, David R.; Mattson, Ronald J.; Yevich, Joseph P.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044376	A1	20000803	WO 1999-US30501	19991221
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2360683	AA	20000803	CA 1999-2360683	19991221
US 6225324	B1	20010501	US 1999-467957	19991221
BR 9916618	A	20011023	BR 1999-16618	19991221
EP 1146871	A1	20011024	EP 1999-968927	19991221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101939	T2	20020521	TR 2001-200101939	19991221
JP 2002535365	T2	20021022	JP 2000-595679	19991221
AU 771234	B2	20040318	AU 2000-27122	19991221
PRIORITY APPLN. INFO.:			US 1999-117651P P	19990128
			WO 1999-US30501 W	19991221

OTHER SOURCE(S): MARPAT 133:135229
GI



I



II

L10 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
AB The title compds. [I; Z = (un)substituted Ph, benzodioxolone, pyridine, etc.; n, n = 1-3; Y = (un)substituted CH2Ph, indol-3-yl], useful antidepressant agents demonstrating potent inhibition of 5-HT reuptake, were prepared Thus, reacting 1-(benzodioxol-5-yl)-4-piperidone (preparation given) with 4-(2-bromo-5-fluorobenzyl)piperidine and NaBH(OAc)3 in THF and AcOH over 4Å sieves afforded 37% II. Compds. I are effective at 5-20 mg/kg/day, when administered orally.
IT **286469-17-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amino-substituted N-aryl or N-heteroaryl cyclic amines as antidepressants)
RN 286469-17-8 CAPLUS
CN Pyridazine, 3-[4-[3-[(2-bromophenyl)methyl]-1-pyrrolidinyl]-1-piperidinyl]-6-chloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1999:571815 CAPLUS
DOCUMENT NUMBER: 131:214191
TITLE: Preparation of 3-(heterocyclylmethoxy)pyridines as nicotinic cholinergic agonists
INVENTOR(S): Abreo, Melwyn A.; Gunn, David E.; Lin, Nan-Horng; Garvey, David S.; Holladay, Mark W.; Ryther, Keith B.
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 391,749, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5948793	A	19990907	US 1995-474873	19950607
CA 2223062	AA	19961219	CA 1996-2223062	19960528
WO 9640682	A1	19961219	WO 1996-US7804	19960528
W: AU, CA, JP, KR, MX				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9658045	A1	19961230	AU 1996-58045	19960528
AU 709784	B2	19990909		
EP 846114	A1	19980610	EP 1996-914786	19960528
EP 846114	B1	20011205		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
JP 2000509011	T2	20000718	JP 1997-500765	19960528
AT 210130	E	20011215	AT 1996-914786	19960528
PT 846114	T	20020531	PT 1996-914786	19960528
ES 2171222	T3	20020901	ES 1996-914786	19960528
HK 1011866	A1	20021011	HK 1998-113169	19981210

PRIORITY APPLN. INFO.: US 1992-959005 B2 19921009
US 1993-126481 B2 19930928
US 1993-129223 B1 19931004
US 1995-391749 B2 19950221
US 1995-474873 A 19950607
US 1995-485537 A 19950607
WO 1996-US7804 W 19960528

OTHER SOURCE(S): MARPAT 131:214191
AB R1Z1CH2OZ2R2 [I; R1 = H, alkyl, allyl; R2 = H, Cl, F, alkyl; Z1 = azetidine-, pyrrolidine-, or piperidine-1,2-diyl; Z2 = (un)substituted pyridine-3,2-diyl] were prepared Thus, (R)-1-methyl-2-pyrrolidinemethanol was etherified by 3-hydroxypyridine to give (R)-MeZ1CH2OZ2H (Z1 = pyrrolidine-1,2-diyl, Z2 = pyridine-3,2-diyl). Data for biol. activity of I were given.
IT **228856-93-7P 228856-96-0P 228857-07-6P**
228857-10-1P 228857-38-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(heterocyclylmethoxy)pyridines as nicotinic cholinergic agonists)
RN 228856-93-7 CAPLUS
CN Pyridazine, 3-chloro-6-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]- (9CI) (CA INDEX NAME)

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry. Rotation (+).



RN 228856-96-0 CAPLUS
CN Pyridazine, 3-chloro-6-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 228857-07-6 CAPLUS
CN Pyridazine, 3-chloro-6-[[(2R)-1-methyl-2-pyrrolidinyl]methoxy]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 228856-93-7
CMF C10 H14 Cl N3 O

Absolute stereochemistry. Rotation (+).



CM 2

CRN 144-62-7
CMF C2 H2 O4

RN 228857-10-1 CAPLUS
CN Pyridazine, 3-chloro-6-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-, (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

L10 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CM 1

CRN 228856-96-0
CMF C10 H14 Cl N3 O

Absolute stereochemistry.



CM 2

CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.



RN 228857-38-3 CAPLUS
CN Pyridazine, 3-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1994:483247 CAPLUS
DOCUMENT NUMBER: 121:83247
TITLE: Unexpected formation of 1-amino-4,4,5,5-tetramethyl-3-(5,5,6,6-tetramethyl-1,4,5,6-tetrahydropyridazin-3-yl)pyrrolidin-2-one
AUTHOR(S): Voss, Jurgen; Roeske, Rudiger
CORPORATE SOURCE: Inst. Org. Chem., Univ. Hamburg, Hamburg, D-20146, Germany
SOURCE: Zeitschrift fuer Naturforschung, B: Chemical Sciences (1994), 49(5), 672-4
CODEN: ZNBSEN; ISSN: 0932-0776
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 121:83247
GI



I II

AB The title compound I is formed on reaction of octamethyldispiro[2.1.2.1]octane-4,8-dione (II) with hydrazine. Its structure is established by x-ray diffraction anal.

IT **156424-84-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and crystal structure of)

RN 156424-84-9 CAPLUS
CN 2-Pyrrolidinone, 1-amino-4,4,5,5-tetramethyl-3-(1,4,5,6-tetrahydro-5,5,6,6-tetramethyl-3-pyridazinyl)- (9CI) (CA INDEX NAME)



L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1993:517098 CAPLUS
DOCUMENT NUMBER: 119:117098
TITLE: Preparation of 2-pyrrolidinone-3-acetates and analogs as cell aggregation inhibitors
INVENTOR(S): Austel, Volkhard; Eisert, Wolfgang; Himmelsbach, Frank; Linz, Guenter; Mueller, Thomas; Pieper, Helmut; Weisenberger, Johannes
PATENT ASSIGNEE(S): Thomae, Dr. Karl, G.m.b.H., Germany
SOURCE: Eur. Pat. Appl., 73 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 528369	A2	19930224	EP 1992-113877	19920814
EP 528369	A3	19930421		
EP 528369	B1	19991124		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4127404	A1	19930225	DE 1991-4127404	19910819
AT 186906	E	19991215	AT 1992-113877	19920814
CA 2076311	AA	19930220	CA 1992-2076311	19920818
NO 9203235	A	19930222	NO 1992-3235	19920818
AU 9221119	A1	19930225	AU 1992-21119	19920818
AU 654372	B2	19941103		
JP 06025227	A2	19940201	JP 1992-219149	19920818
ZA 9206205	A	19940218	ZA 1992-6205	19920818
IL 102847	A1	19961114	IL 1992-102847	19920818
US 5455348	A	19951003	US 1993-173603	19931223
PRIORITY APPLN. INFO.:			DE 1991-4127404 A	19910819
			US 1992-929870 B1	19920814

OTHER SOURCE(S): MARPAT 119:117098
GI



I

AB EYAX1X2X3X4X5B [A = (substituted) bivalent (oxo)alkyleneimino; B = NH2, C(:NH)NH2, NHC(:NH)NH2, etc.; E = CO2H, alkoxycarbonyl, etc.; X1 = bond, alkylene; X2 = bond, O, NH, SO2NH, etc.; X3, X5 = (hetero)cycloalkylene, (hetero)arylene, etc.; X4 = bond, O, CH2, CO, NH, etc.; X3X4X5 = phenylene, (CH2)3-5, etc.; Y = alkylene, NHCH2, OCH2, etc.] were prepared Thus, 4-(5-cyano-2-pyridyl)phenol (preparation given) was condensed with

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
(3S,5S)-3-[(tert-butyloxycarbonyl)methyl]-5-[(methanesulfonyloxy)methyl]-2-pyrrolidinone and the product converted in 2 steps to title compd. (3S,5S)-I which had ED50 of 0.06 μM against collagen-induced platelet aggregation in vitro.

IT **149354-16-5P 149354-18-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of cell aggregation inhibitors)

RN 149354-16-5 CAPLUS
CN Benzonitrile, 4-[6-[[5-oxo-1-(3-phenylpropyl)-4-(2-propenyl)-2-pyrrolidinyl]methoxy]-3-pyridazinyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149354-18-7 CAPLUS
CN Benzonitrile, 4-[6-[[[5-oxo-1-(3-phenylpropyl)-4-(2-propenyl)-2-pyrrolidinyl]methyl]amino]-3-pyridazinyl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **149354-58-5P 149354-59-6P 149354-60-9P**
149354-61-0P 149354-62-1P 149354-76-7P
149354-77-8P 149354-78-9P 149354-79-0P
149355-32-8P 149355-33-9P 149355-37-3P
149355-38-4P 149355-39-5P 149355-41-9P
149355-43-1P 149355-53-3P 149367-96-4P
149377-23-1P 149377-24-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as cell aggregation inhibitor)

RN 149354-58-5 CAPLUS

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-3-pyridazinyl]oxy]methyl]-2-oxo-1-(3-phenylpropyl)-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149354-59-6 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-3-pyridazinyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149354-60-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149354-61-0 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-2-methyl-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149354-62-1 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 149354-78-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-3-pyridazinyl]amino]methyl]-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 149354-79-0 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149354-76-7 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-3-pyridazinyl]oxy]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 149354-77-8 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-3-pyridazinyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



● HCl

RN 149355-32-8 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-(4-cyanophenyl)-3-pyridazinyl]oxy]methyl]-2-oxo-1-(3-phenylpropyl)-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149355-33-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-(4-cyanophenyl)-3-pyridazinyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149355-37-3 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-(4-cyanophenyl)-3-pyridazinyl]oxy]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Absolute stereochemistry.



RN 149355-38-4 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-(4-cyanophenyl)-3-pyridazinyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149355-39-5 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-(4-cyanophenyl)-3-pyridazinyl]amino]methyl]-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149355-53-3 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-(4-cyanophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-1-(3-phenylpropyl)-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149367-96-4 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[6-[4-(aminoiminomethyl)phenyl]-3-pyridazinyl]amino]methyl]-2-oxo-, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149377-23-1 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 149355-41-9 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-(4-cyanophenyl)-2,3-dihydro-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 149355-43-1 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-(4-cyanophenyl)-2,3-dihydro-2-methyl-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, methyl ester, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

● HCl

RN 149377-24-2 CAPLUS
CN 3-Pyrrolidineacetic acid, 5-[[[[6-[4-(aminoiminomethyl)phenyl]-2,3-dihydro-2-methyl-3-oxo-4-pyridazinyl]carbonyl]amino]methyl]-2-oxo-, methyl ester, monohydrochloride, (3S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1992:557539 CAPLUS
DOCUMENT NUMBER: 117:157539
TITLE: Characterization of polymorphs and solvates of 3-amino-1-(m-trifluoromethylphenyl)-6-methyl-1H-pyridazin-4-one
AUTHOR(S): Chauvet, Alain; Masse, Jacqueline; Ribet, Jean Paul; Bigg, Dennis; Autin, Jean Marie; Maurel, Jean Louis; Patoiseau, Jean Francois; Jaud, Joel
CORPORATE SOURCE: Lab. Chim. Gen. Miner., Fac. Pharm., Montpellier, 34100, Fr.
SOURCE: Journal of Pharmaceutical Sciences (1992), 81(8), 836-41
CODEN: JPMSAE; ISSN: 0022-3549
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB The characterization of two polymorphs of the title compound F-2692 (I) by DSC, NMR spectroscopy, thermogravimetry, thermomicroscopy, IR spectroscopy, and x-ray diffractometry is described. Both polymorphs are crystalline, with form being more stable at temps. <160°. The thermal behavior was studied at different rates of heating, and the enthalpies of transition were calculated from DSC data. The transformation of aqueous suspensions of form I to the water-stable form II is described, and the heats of solution and intrinsic aqueous dissoln. rates of both polymorphs were determined F-2692 also formed solvates with DMSO and 1-methyl-2-**pyrrolidinone**. The solvates were studied by thermogravimetry, DSC, and IR spectroscopy.
IT **143556-16-5P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and properties of)
RN 143556-16-5 CAPLUS
CN 4(1H)-Pyridazinone, 3-amino-6-methyl-1-[3-(trifluoromethyl)phenyl]-, compd. with 1-methyl-2-pyrrolidinone (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 133220-91-4
CMF C12 H10 F3 N3 O

L10 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



CM 2

CRN 872-50-4
CMF C5 H9 N O

L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1987:617646 CAPLUS
DOCUMENT NUMBER: 107:217646
TITLE: Preparation of diazinylpiperidines as psychoanaleptic agents
INVENTOR(S): Mattson, Ronald J.; Yevich, Joseph P.
PATENT ASSIGNEE(S): Bristol-Myers Co., USA
SOURCE: Fr. Demande, 30 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2584408	A1	19870109	FR 1986-9666	19860703
FR 2584408	B1	19890602		
ZA 8604594	A	19870225	ZA 1986-4594	19860619
FI 8602830	A	19870109	FI 1986-2830	19860703
FI 88300	B	19930115		
FI 88300	C	19930426		
BE 905061	A1	19870107	BE 1986-216887	19860707
DK 8603239	A	19870109	DK 1986-3239	19860707
DK 170441	B1	19950904		
NO 8602729	A	19870109	NO 1986-2729	19860707
NO 167389	B	19910722		
NO 167389	C	19911030		
SE 8603026	A	19870109	SE 1986-3026	19860707
SE 462491	B	19900702		
SE 462491	C	19901025		
AU 8659787	A1	19870115	AU 1986-59787	19860707
AU 595215	B2	19900329		
GB 2177692	A1	19870128	GB 1986-16504	19860707
GB 2177692	B2	19890712		
NL 8601763	A	19870202	NL 1986-1763	19860707
HU 41405	A2	19870428	HU 1986-2835	19860707
HU 199455	B	19900228		
CH 671579	A	19890915	CH 1986-2740	19860707
IL 79351	A1	19900319	IL 1986-79351	19860707
CA 1272725	A1	19900814	CA 1986-513196	19860707
DE 3622842	A1	19870305	DE 1986-3622842	19860708
DE 3622842	C2	19960829		
JP 62070371	A2	19870331	JP 1986-160672	19860708
JP 04005675	B4	19920203		
CN 86104681	A	19870527	CN 1986-104681	19860708
CN 1012364	B	19910417		
ES 2000476	A6	19880301	ES 1986-190	19860708
AT 8601852	A	19920815	AT 1986-1852	19860708
AT 395850	B	19930325		

PRIORITY APPLN. INFO.: US 1985-753006 A 19850708
US 1986-868468 A 19860530

GI For diagram(s), see printed CA Issue.
AB The title compds. [I; R1 = H, C1-4 alkyl; R2 = (un)substituted pyridazinyl, pyrimidinyl, pyrazinyl; X = CH2CH2, Z = CH2; X = 1,2-C6H4, Z = CH2, CO] were prepared as psychoanaleptic agents.
1-(4-Pyridinylmethyl)-2-**pyrrolidinone** [prepared from 4-(chloromethyl)pyridine and 2-**pyrrolidinone**] was hydrogenated over PtO in HCl/EtOH to give the corresponding piperidine derivative which was stirred 14 h with 2,4-dichloropyrimidine in DMF containing Na2CO3 to give

L10 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
[(pyrimidinylpiperidinyl)methyl]]**pyrrolidinone** II. At 0.5 mg/kg s.c. and orally II suppressed electroconvulsive shock-induced amnesia in mice.
IT **111247-41-7P 111247-53-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as psychoanaleptic agent)
RN 111247-41-7 CAPLUS
CN 2-Pyrrolidinone, 1-[[1-(6-chloro-3-pyridazinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 111247-53-1 CAPLUS
CN 2-Pyrrolidinone, 1-[[1-(5,6-dichloro-4-pyridazinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1986:497487 CAPLUS
DOCUMENT NUMBER: 105:97487
TITLE: 4,5-Dihydro-3(2H)-pyridazinones
INVENTOR(S): Zoller, Gerhard; Beyerle, Rudi; Just, Melitta; Bohn, Helmut; Piero, Martorana; Nitz, Rolf Eberhard
PATENT ASSIGNEE(S): Cassella A.-G., Fed. Rep. Ger.
SOURCE: Ger. Offen., 32 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
DE 3434680	A1	19860403	DE 1984-3434680		19840921
US 4816454	A	19890328	US 1985-775420		19850912
DK 8504171	A	19860322	DK 1985-4171		19850913
FI 8503519	A	19860322	FI 1985-3519		19850913
JP 61085367	A2	19860430	JP 1985-204564		19850918
EP 175363	A2	19860326	EP 1985-111838		19850919
EP 175363	A3	19870311			
EP 175363	B1	19900117			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
AT 49594	E	19900215	AT 1985-111838		19850919
ES 547169	A1	19860316	ES 1985-547169		19850920
AU 8547661	A1	19860410	AU 1985-47661		19850920
ZA 8507225	A	19860528	ZA 1985-7225		19850920
HU 40646	A2	19870128	HU 1985-3555		19850920
PRIORITY APPLN. INFO.:			DE 1984-3434680	A	19840921
			DE 1985-3522193	A	19850621
			EP 1985-111838	A	19850919

GI



I II

AB The title compds. [I; R = substituted Ph, (un)substituted benzoxazinyl, pyrrolyl, pyrazolyl, indolyl; R1, R2 = H, alkyl] were prepared as cardiovascular agents (no data). Thus, 1-phenyl-2-pyrrolidinone underwent Friedel-Craft acylation with methylmaleic anhydride and the resulting butenoic acid derivative (69% yield) was reduced with Zn dust in HOAc to give 46% (pyrrolidinylphenyl)butanoate II. This was refluxed in EtOH with N2H4.H2O to give 81% I [R = 4-(2-oxo-1-pyrrolidinyl)phenyl, R1 = Me, R2 = H]. Tablets were prepared each containing I 50, lactose 150, white cornstarch 230, polyvinylpyrrolidone 15, and Mg stearate 5 mg.
IT 103876-73-9P 103876-76-2P 103876-78-4P

L10 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as cardiovascular agent)
RN 103876-73-9 CAPLUS
CN 3(2H)-Pyridazinone, 4,5-dihydro-5-methyl-6-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 103876-76-2 CAPLUS
CN 3(2H)-Pyridazinone, 4,5-dihydro-6-[4-(2-oxo-1-pyrrolidinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 103876-78-4 CAPLUS
CN Urea, N-[2-(2-oxo-1-pyrrolidinyl)ethyl]-N'-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]- (9CI) (CA INDEX NAME)



10/ 725,267

=> d his

(FILE 'HOME' ENTERED AT 11:03:21 ON 01 DEC 2005)

FILE 'REGISTRY' ENTERED AT 11:03:30 ON 01 DEC 2005
L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 STRUCTURE UPLOADED
L4 0 S (L1 OR L2 OR L3) SAMPLE
L5 0 S (L1 OR L2 OR L3) FULL
L6 1620 S PYRIDAZ? AND PYRROLIDIN?
L7 0 S PYRIDAZ? WITH PYRROLIDIN?
L8 0 S PYRIDAZ? SAME PYRROLIDIN?

FILE 'CAPLUS' ENTERED AT 11:06:45 ON 01 DEC 2005
L9 523 S L6
L10 14 S L9 AND (PYRROLIDINONE OR "OXO-PYRROLIDINYL")

=> log y